Results 41 to 50 of about 8,372 (190)

Ziprasidone: A New Atypical Antipsychotic Agent

, 2001
Objective:To evaluate ziprasidone for the treatment of schizophrenia with respect to its pharmacology, pharmacokinetics, adverse effect profiles, and drug interaction potential.Data Source:A MEDLINE search (1966-May 2001) was conducted for primary and ...
Jacqueline P Merrick, Bong G Yu
core   +1 more source

Annual Research Review: Psychosis in children and adolescents: key updates from the past 2 decades on psychotic disorders, psychotic experiences, and psychosis risk

Journal of Child Psychology and Psychiatry, Volume 66, Issue 4, Page 460-476, April 2025.
Psychosis in children and adolescents has been studied on a spectrum from (common) psychotic experiences to (rare) early‐onset schizophrenia spectrum disorders. This research review looks at the state‐of‐the‐art for research across the psychosis spectrum, from evidence on psychotic experiences in community and clinical samples of children and ...
Ian Kelleher
wiley   +1 more source

ZIPRASIDONE: A NEW ATYPICAL ANTIPSYCHOTIC AGENT

Psychiatry and Clinical Psychopharmacology, 2021
Ziprasidone is a benzisothiazol piperazine derivative with a higher therapeutic efficacy and a favourable tolerability profile in the treatment of schizophrenia. Ziprasidone has a high 5-HT2 to D2 receptor binding ratio and also binds with high affinity
Artuner Deveci, Ayşen Esen Danacı
doaj  

Exploring Current Emergency Medical Services Approaches to Manage Agitated Older Adult Patients: An Analysis of Statewide Protocols

Journal of the American Geriatrics Society, EarlyView.
Most state EMS protocols provide guidance on management of agitated patients, including use of physical restraints and chemical sedatives, yet older adult‐specific modifications or dosing guidance are uncommon. ABSTRACT Background Agitation in older adults presents unique challenges for emergency medical services (EMS) clinicians.
Joshua Lachs, Rana Barghout, William Haussner, David Hancock, Emily Benton, Maia Dorsett, Gregory Peters, Rebecca Cash, Joseph Holley, Tony Rosen   +9 more
wiley   +1 more source

Ziprasidone decreases cortisol excretion in healthy subjects

, 2005
Aims To determine the influence of the atypical antipsychotic ziprasidone on cortisol excretion. Methods In a double-blind, placebo-controlled, randomized cross-over design 11 healthy male subjects were studied twice for 2 consecutive nights (N1 ...
Meier, A., Neumann, A. C., Huether, Gerald, Jordan, W., Ruther, Eckart, Cohrs, Stefan, Rodenbeck, Andrea   +6 more
core   +1 more source

Prophylactic Olanzapine Versus Placebo in Comatose Survivors of Out‐of‐Hospital Cardiac Arrest: Protocol for a Multicenter Randomized Comparison Within the Danish Out‐of‐Hospital Cardiac Arrest (DANOHCA) Trial

Acta Anaesthesiologica Scandinavica, Volume 70, Issue 7, August 2026.
ABSTRACT Background Delirium is a frequent complication in comatose Out‐of‐Hospital Cardiac Arrest (OHCA) survivors requiring postresuscitation intensive care and is associated with higher mortality and longer hospitalization. Despite this, there is no established pharmacologic strategy for delirium prevention in OHCA survivors.
Benedikte Liebetrau, Anders M. Grejs, Martin A. S. Meyer, Lars P. K. Andersen, Sören Möller, Simon Mølstrøm, Jacob E. Møller, Henrik Schmidt, Steffen Christensen, Jesper Kjærgaard, Christian Hassager, Bodil S. Rasmussen, Jo B. Andreasen   +12 more
wiley   +1 more source

Switching a ziprasidone: l’esperienza clinica italiana.

, 2006
This article presents practical recommendations of a panel of Italian psychiatrists based on their clinical experience in using the new antipsychotic drug ziprasidone.
Mauri Massimo Carlo, Rossi Alessandro, Paladini Carlo, Zarrillo Antonio   +3 more
core   +1 more source

Strategies for successful clinical management of schizophrenia with ziprasidone

, 2010
IMPORTANCE OF THE FIELD: This review addresses practical clinical issues related to the use of ziprasidone in the treatment of schizophrenia using information from clinical trials, unpublished data, manufacturer's information, and input from an expert ...
José Manuel Montes, ZINK, M., Ilkka Larmo, ROSSI, A., Alessandro Rossi, CAÑAS, F., LEVY, P., PAPAGEORGIOU, G., Fernando Cañas, Pedro Levy, FAGIOLINI, A., Mathias Zink, LARMO, I., MONTES, J. M., GALLHOFER, B., Georgios Papageorgiou, Bernd Gallhofer, Andrea Fagiolini   +17 more
core   +2 more sources

Effectiveness of a Psychiatrist‐Led Clinic for Metabolic Health in Severe Mental Illness: A Retrospective Chart Review Study

Acta Psychiatrica Scandinavica, Volume 154, Issue 1, Page 74-88, July 2026.
ABSTRACT Background Psychotropic medications are associated with serious metabolic adverse effects, which contribute to an increased risk of cardiometabolic comorbidities in patients with severe mental illness (SMI). Several intervention strategies are available to mitigate these metabolic adverse effects; however, data on their utility in real‐world ...
Nicolette Stogios, Femin Prasad, Riddhita De, Kateryna Maksyutynska, Akash PrasannaKumar, Vittal Korann, Tariq Ahmed, Marcos Sanches, Leah Burton, Mohammed A. Alarabi, Tanner Isinger, Michelle Desanti, Rebecca Oliveira, Daphne J. Korczak, Ariel Graff‐Guerrero, Gary Remington, Margaret K. Hahn, Sri Mahavir Agarwal   +17 more
wiley   +1 more source

Ziprasidone in the Treatment of Delusional Parasitosis

, 2012
Delusional parasitosis is characterized by a patient’s fixed false belief of being infested with parasites or small creatures. The first-line treatment options are typical antipsychotics such as pimozide.
P. Contreras-Ferrer, M. García Bustínduy, M. Rodríguez-Martín, N. Merino de Paz, P. Contreras-Ferrer, M.R. Cejas-Mendez, R. Souto   +6 more
core   +1 more source